The anti-tumor effect of cladoloside C2 was significantly inhibited in CerS6 shRNA-silenced K562 and HL-60 xenograft models (Figure 7B), with 75.6% and 84.1% inhibition of tumor growth in NC-shRNA-1 and NC-shRNA-3 xenograft models, respectively, vs. 15.6% and 25.6% inhibition of tumor growth by cladoloside C2 in CerS6-shRNA-1 and CerS6-shRNA-5 xenograft models, respectively. Here, CERS6 is linked to neoplasm.